VivoSeq
Other

Fusion Rate

0

Pipeline Programs↗

0

Active Trials↗

2

Companies Involved↗

Fusion Rate is an early-stage landscape with 0 programs across 2 companies. The most active players are Luye Pharma Group Ltd., Arrowhead Pharmaceuticals.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.

0 programs

PreclinicalArrowhead Pharmaceuticals logo

Arrowhead Pharmaceuticals

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

9

clinical trials

Completed7 · 78%
Unknown status2 · 22%

Clinical Trials

Trial Activity

9 trials

An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects
Completed·Luye Pharma Group Ltd. logoLuye Pharma Group Ltd.·Phase 1·NCT05857449·23 enrolled
A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers
Completed·Arrowhead Pharmaceuticals logoArrowhead Pharmaceuticals·Phase 1·NCT02535416·40 enrolled
Flat and Circadian Insulin Infusion Rates in Continuous Subcutaneous Insulin Infusion
Completed·IImperial College London·N/A·NCT04267770·17 enrolled
GLASSIA Infusion Rate Study
Completed·BBaxalta now part of Shire·Phase 4·NCT01651351·30 enrolled
Comparison of the Effect on the Glucose Infusion Rates Between Inhaled Technosphere Insulin and a Subcutaneous Injection of Regular Human Insulin
Completed·MMannkind Corporation·Phase 1·NCT00511979·12 enrolled
Infusion Rate and Volume Kinetics for Hyperoncotic Albumine in Healthy Subjects
Completed·UUniversity Hospital, Linkoeping·Phase 4·NCT03453320·12 enrolled
Changes of the Infusion Rate in Insulin Pump Treatment
Completed·—·Phase 4·NCT00449839·10 enrolled
Panzyga in CIDP Administered at Different Infusion Rates
Unknown status·—·Phase 3·NCT03166527·30 enrolled
Importance of the Infusion Rate for the Plasma Expanding Effect of 5% Albumin in the Septic Patient
Unknown status·—·Phase 4·NCT03153306·60 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)